STOCK TITAN

Khiron Life Sciences Corp - KHRNF STOCK NEWS

Welcome to our dedicated news page for Khiron Life Sciences (Ticker: KHRNF), a resource for investors and traders seeking the latest updates and insights on Khiron Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Khiron Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Khiron Life Sciences's position in the market.

Rhea-AI Summary
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) announces the completion of the sale of its European subsidiaries to 2518542 Alberta Ltd. for $3,000,000. The sale includes Khiron Europe GmbH, Zerenia Clinics Limited, PharmaDrug Production GmbH, Khiron Life Sciences UK Limited, and Khiron Life Sciences Spain SL. The base purchase price was partially satisfied by a pre-paid deposit of $500,000 and prior growth capital advances. Further adjustments to the purchase price were made for closing working capital and indebtedness, resulting in no further amount owed and no vendor take-back promissory note delivered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Khiron Life Sciences Corp. (TSXV: KHRN) (OTC Pink: KHRNF) announced an amended and restated share purchase agreement with 2518542 Alberta Ltd., a company controlled by Avonlea Drewry Holdings Inc., for the purchase and sale of the Company's European subsidiaries. The Purchaser will acquire the European subsidiaries for an aggregate base purchase price of $3,000,000, subject to certain closing and post-closing adjustments. The option to acquire the Company's Colombian subsidiary, Zerenia S.A.S., was removed to satisfy a condition for the approval of the Transaction by the TSX Venture Exchange. The Company also received conditional approval of the Transaction from the TSXV and approvals pursuant to the German Foreign Trade and Payments Act and the German Foreign Trade and Payments Regulation in respect of the sale and purchase of the issued and outstanding shares of Pharmadrug Production GmbH. The sale and purchase of the issued and outstanding shares of Pharmadrug is expected to occur on or before November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Khiron Life Sciences Corp. has agreed to a $500,000 refundable deposit from 2518542 Alberta Ltd. for the possible sale of its European subsidiaries. The completion of the transaction is subject to negotiation and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.68%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
none
Khiron Life Sciences Corp

OTC:KHRNF

KHRNF Rankings

KHRNF Stock Data

6.23M
211.63M
0.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Toronto